Fri, 09/06/2024 - 14:57
fitness info and more right in your inbox.
A Compilation Of Studies On Ozempic
GASTROINTESTINAL ISSUES (Pancreatitis, Pancreatic Cancer, Stomach Paralysis, Intestinal Blockage, Gallbladder Stones, Biliary Disease)
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Batel-Marques F, Macedo AF. Diabetes Res Clin Pract. 2012;98:271–284. [PubMed] [Google Scholar]
First epidemiological study links popular weight-loss drugs to stomach paralysis, other serious gastrointestinal conditionshttps://news.ubc.ca/2023/10/diabetes-weight-loss-drug-leads-to-gastrointestinal-issues/#:~:text=That's%20according%20to%20new%20research,paralysis%2C%20pancreatitis%20and%20bowel%20obstruction
Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgeryhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891341/
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Gastroenterology. 2011;141:150–156. [PMC free article] [PubMed] [Google Scholar]
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. JAMA Intern Med. 2013;173:534–539.[PubMed] [Google Scholar]
Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Diabetes MetabSyndr. 2022;16:102427. [PubMed] [Google Scholar]
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Liu L, Chen J, Wang L, Chen C, Chen L. Front Endocrinol (Lausanne) 2022;13:1043789. [PMC free article] [PubMed] [Google Scholar]
Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. KnapenLM, de Jong RG, Driessen JH, et al. Diabetes ObesMetab. 2017;19:401–411. [PubMed] [Google Scholar]
Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Faillie JL, BabaiS, Crépin S, et al. Acta Diabetol. 2014;51:491–497. [PubMed] [Google Scholar]
Diabetes mellitus and the risk of pancreatitis: a systematic review and meta-analysis of cohort studies. Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Pancreatology. 2020;20:602–607. [PubMed] [Google Scholar]
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–156. [PMC free article] [PubMed] [Google Scholar]
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Losshttps://jamanetwork.com/journals/jama/fullarticle/2810542
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitushttps://pubmed.ncbi.nlm.nih.gov/27478902/
THYROID CANCER
GLP-1 Receptor Agonists and the Risk of Thyroid Cancerhttps://diabetesjournals.org/care/article/46/2/384/147888/GLP-1-Receptor-Agonists-and-the-Risk-of-Thyroid
Novo Nordisk says EMA raised safety signal on drugs including semaglutidehttps://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-shares-slip-ema-drug-safety-signal-2023-06-22/
Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trialshttps://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15382#:~:text=All%20cases%20of%20thyroid%20cancer,3.12%5D;%20P%20=%200.05
SARCOPENIA
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitushttps://pubmed.ncbi.nlm.nih.gov/32628589/
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials https://pubmed.ncbi.nlm.nih.gov/38629387/#:~:text=Noteworthy%20decreases%20in%20lean%20mass,primarily%20through%20fat%20mass%20reduction
DEPRESSION / SUICIDALITY
Patients being prescribed GLP1 are more than 20% more likely to later be prescribed anti depressants.
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822453